BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 24108812)

  • 1. Disease-free survival as a surrogate for overall survival in adjuvant trials of gastric cancer: a meta-analysis.
    Oba K; Paoletti X; Alberts S; Bang YJ; Benedetti J; Bleiberg H; Catalano P; Lordick F; Michiels S; Morita S; Ohashi Y; Pignon JP; Rougier P; Sasako M; Sakamoto J; Sargent D; Shitara K; Cutsem EV; Buyse M; Burzykowski T;
    J Natl Cancer Inst; 2013 Nov; 105(21):1600-7. PubMed ID: 24108812
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Disease-free survival as a surrogate for overall survival in neoadjuvant trials of gastroesophageal adenocarcinoma: Pooled analysis of individual patient data from randomised controlled trials.
    Ronellenfitsch U; Jensen K; Seide S; Kieser M; Schwarzbach M; Slanger TE; Burmeister B; Kelsen D; Niedzwiecki D; Piessen G; Schuhmacher C; Urba S; van de Velde C; Ychou M; Hofheinz R; Lorenzen S
    Eur J Cancer; 2019 Dec; 123():101-111. PubMed ID: 31678767
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase III Trial to Compare Adjuvant Chemotherapy With Capecitabine and Cisplatin Versus Concurrent Chemoradiotherapy in Gastric Cancer: Final Report of the Adjuvant Chemoradiotherapy in Stomach Tumors Trial, Including Survival and Subset Analyses.
    Park SH; Sohn TS; Lee J; Lim DH; Hong ME; Kim KM; Sohn I; Jung SH; Choi MG; Lee JH; Bae JM; Kim S; Kim ST; Park JO; Park YS; Lim HY; Kang WK
    J Clin Oncol; 2015 Oct; 33(28):3130-6. PubMed ID: 25559811
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Progression-free survival as a surrogate for overall survival in advanced/recurrent gastric cancer trials: a meta-analysis.
    Paoletti X; Oba K; Bang YJ; Bleiberg H; Boku N; Bouché O; Catalano P; Fuse N; Michiels S; Moehler M; Morita S; Ohashi Y; Ohtsu A; Roth A; Rougier P; Sakamoto J; Sargent D; Sasako M; Shitara K; Thuss-Patience P; Van Cutsem E; Burzykowski T; Buyse M;
    J Natl Cancer Inst; 2013 Nov; 105(21):1667-70. PubMed ID: 24108811
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adjuvant chemotherapy, p53, carcinoembryonic antigen expression and prognosis after D2 gastrectomy for gastric adenocarcinoma.
    He MM; Zhang DS; Wang F; Wang ZQ; Luo HY; Ren C; Jin Y; Chen DL; Xu RH
    World J Gastroenterol; 2014 Jan; 20(1):264-73. PubMed ID: 24415881
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Surrogate end-points for overall survival in 22 neoadjuvant trials of gastro-oesophageal cancers.
    Petrelli F; Tomasello G; Barni S
    Eur J Cancer; 2017 May; 76():8-16. PubMed ID: 28262586
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of efficacy in adjuvant chemotherapy regimens in patients with radically resected gastric cancer : a propensity-matched analysis.
    Quan R; Huang J; Chen H; Liao Y; Lv W; Chen N; Liu J; Zhang H; Xu D
    Oncotarget; 2016 Nov; 7(46):76316-76326. PubMed ID: 27602756
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Retrospective analysis of adjuvant chemotherapy for curatively resected gastric cancer.
    Deng W; Wang QW; Zhang XT; Lu M; Li J; Li Y; Gong JF; Zhou J; Lu ZH; Shen L
    World J Gastroenterol; 2014 Mar; 20(12):3356-63. PubMed ID: 24696615
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Disease-free survival as a surrogate endpoint for overall survival in adjuvant trials of pancreatic cancer: a meta-analysis of 20 randomized controlled trials.
    Nie RC; Zou XB; Yuan SQ; Chen YB; Chen S; Chen YM; Chen GM; Chen XJ; Luo TQ; Li SM; Duan JL; Wang Y; Li YF
    BMC Cancer; 2020 May; 20(1):421. PubMed ID: 32410591
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Disease-free survival is not a surrogate endpoint for overall survival in adjuvant trials of pancreatic cancer: a systematic review of randomized trials.
    Petrelli F; Tomasello G; Ghidini M; Lonati V; Passalacqua R; Barni S
    HPB (Oxford); 2017 Nov; 19(11):944-950. PubMed ID: 28764887
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adjuvant chemotherapy in completely resected gastric cancer: a randomized phase III trial conducted by GOIRC.
    Di Costanzo F; Gasperoni S; Manzione L; Bisagni G; Labianca R; Bravi S; Cortesi E; Carlini P; Bracci R; Tomao S; Messerini L; Arcangeli A; Torri V; Bilancia D; Floriani I; Tonato M; ; Dinota A; Strafiuso G; Corgna E; Porrozzi S; Boni C; Rondini E; Giunta A; Monzio Compagnoni B; Biagioni F; Cesari M; Fornarini G; Nelli F; Carboni M; Cognetti F; Enzo MR; Piga A; Romiti A; Olivetti A; Masoni L; De Stefanis M; Dalla Mola A; Camera S; Recchia F; De Filippis S; Scipioni L; Zironi S; Luppi G; Italia M; Banducci S; Pisani Leretti A; Massidda B; Ionta MT; Nicolosi A; Canaletti R; Biscottini B; Grigniani F; Di Costanzo F; Rovei R; Croce E; Carroccio R; Gilli G; Cavalli C; Olgiati A; Pandolfi U; Rossetti R; Natalini G; Foa P; Oldani S; Bruno L; Cascinu S; Catalano G; Catalano V; Lungarotti F; Farris A; Sarobba MG; Trignano M; Muscogiuri A; Francavilla F; Figoli F; Leoni M; Papiani G; Orselli G; Antimi M; Bellini V; Cabassi A; Contu A; Pazzola A; Frignano M; Lastraioli E; Saggese M; Bianchini D; Antonuzzo L; Mela M; Camisa R
    J Natl Cancer Inst; 2008 Mar; 100(6):388-98. PubMed ID: 18334706
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Disease-free survival as a surrogate for overall survival in HR+/HER2- early breast cancer: A correlation analysis.
    Untch M; Pérol D; Mayer EL; Cortes J; Nusch A; Cameron D; Barrios C; Delea T; Danyliv A; Mishra N; Gupta R; Pathak P; Fasching PA
    Eur J Cancer; 2024 May; 202():113977. PubMed ID: 38460476
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adjuvant albumin-bound paclitaxel combined with S-1 vs. oxaliplatin combined with capecitabine after D2 gastrectomy in patients with stage III gastric adenocarcinoma: a phase III multicenter, open-label, randomized controlled clinical trial protocol.
    Cheng X; Wu D; Xu N; Chen L; Yan Z; Chen P; Zhou L; Yu J; Cui J; Li W; Wang C; Feng W; Wei Y; Yu P; Du Y; Ying J; Xu Z; Yang L; Zhang Y
    BMC Cancer; 2021 Jan; 21(1):56. PubMed ID: 33435909
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adjuvant treatment combining cellular immunotherapy with chemotherapy improves the clinical outcome of patients with stage II/III gastric cancer.
    Wang Y; Wang C; Xiao H; Niu C; Wu H; Jin H; Yao C; He H; Tian H; Han F; Li D; Han W; Xu J; Chen J; Cui J; Li W
    Cancer Med; 2017 Jan; 6(1):45-53. PubMed ID: 27790867
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of disease-free survival as an intermediate metric of overall survival in patients with localized renal cell carcinoma: A trial-level meta-analysis.
    Harshman LC; Xie W; Moreira RB; Bossé D; Ruiz Ares GJ; Sweeney CJ; Choueiri TK
    Cancer; 2018 Mar; 124(5):925-933. PubMed ID: 29266178
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reevaluating Disease-Free Survival as an Endpoint vs Overall Survival in Stage III Adjuvant Colon Cancer Trials.
    Yin J; Salem ME; Dixon JG; Jin Z; Cohen R; DeGramont A; Van Cutsem E; Taieb J; Alberts SR; Wolmark N; Schmoll HJ; Saltz LB; George TJ; Goldberg RRM; Kerr R; Lonardi S; Yoshino T; Yothers G; Grothey A; Andre T; Shi Q
    J Natl Cancer Inst; 2022 Jan; 114(1):60-67. PubMed ID: 34505880
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Effectiveness of precautionary chemotherapy in gastric cancer].
    Rimassa L; Campagnoli E; Biancofiore G
    Tumori; 2000; 86(5 Suppl 2):S5-13. PubMed ID: 11195303
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Timing of surgery after neoadjuvant chemotherapy for gastric cancer: Impact on outcomes.
    Liu Y; Zhang KC; Huang XH; Xi HQ; Gao YH; Liang WQ; Wang XX; Chen L
    World J Gastroenterol; 2018 Jan; 24(2):257-265. PubMed ID: 29375211
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adjuvant chemotherapy with epirubicin, leucovorin, 5-fluorouracil and etoposide regimen in resected gastric cancer patients: a randomized phase III trial by the Gruppo Oncologico Italia Meridionale (GOIM 9602 Study).
    De Vita F; Giuliani F; Orditura M; Maiello E; Galizia G; Di Martino N; Montemurro F; Cartenì G; Manzione L; Romito S; Gebbia V; Ciardiello F; Catalano G; Colucci G;
    Ann Oncol; 2007 Aug; 18(8):1354-8. PubMed ID: 17525087
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of oxaliplatin in the adjuvant setting of different Lauren's type of gastric adenocarcinoma after D2 gastrectomy: a real-world study.
    Cheng X; Yu S; Wang Y; Cui Y; Li W; Yu Y; Tang C; Jiang H; Ji Y; Sun Y; Wang X; Shen Z; Liu F; Liu TS
    Gastric Cancer; 2019 May; 22(3):587-597. PubMed ID: 30426294
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.